Table 1 Descriptive characteristics of patients
Patient | Diagnosis | TNF-α inhibitor | DMARD | Age in years, BMI | Sex, race | Episodes of low glucose readings | Venous glucose value, mg/dL | Total duration on TNF-α inhibitor | Time before development of hypoglycemia | History of diabetes? | Family history of diabetes? | History of gestational diabetes? |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | RA | Infliximab, etanercept | Hydroxychloroquine | 68, 22.0 | Female, Caucasian | 2 | 67, 68 | 13 months (infliximab), 10 months (abatacept) | 6 months, 10 months | No | No | No |
2 | RA, SLE, CREST syndrome | Infliximab | Hydroxychloroquine, MTX | 54, 32.4 | Female, Caucasian | 1 | 66 | 13 months (infliximab) | 8 months | No | Yes | No |
3 | RA | Infliximab | Leflunomide | 62, 22.1 | Female, Caucasian | 1 | 60 | 24 months (infliximab) | 4 months | No | No | No |
4 | RA, SpA | Adalimumab | Hydroxychloroquine | 29, 18.3 | Female, Caucasian | 1 | 67 | 3 months (adalimumab) | 3 months | No | No | No |
5 | RA, FMS | Certolizumab, infliximab | Leflunomide | 35, 19.3 | Female, Caucasian | 2 | 69, 63 | 11 months (abatacept), 14 months (infliximab) | 2 months, 3 months | No | No | No |
6 | RA, SLE, CREST syndrome | Adalimumab, certolizumab, infliximab | Leflunomide | 55, 24.5 | Female, Caucasian | 4 | 63, 62, 62, 68 | 17 months (adalimumab), 17 months (certolizumab) | 4 months, 14 months, 15 months, 6 months | No | No | No |
7 | RA, vWD | Adalimumab, golimumab | MTX | 30, 19.6 | Female, Caucasian | 3 | 68, 58 | 11 months (adalimumab), 3 months (golimumab) | 6 months, 1 month | No | No | No |
8 | RA, SpA, FMS | Adalimumab | None | 47, 21.4 | Female, Caucasian | 1 | 54 | 11 months (adalimumab) | 2 months | No | No | No |
9 | RA, FMS | Infliximab | Hydroxychloroquine | 65, 19.8 | Female, Caucasian | 1 | 64 | 24 months (infliximab) | 5 months | No | No | No |